122 related articles for article (PubMed ID: 37657990)
1. The impact of modified staining method on HER2 immunohistochemical staining for HER2-low breast cancer.
Chen YY; Yang CF; Hsu CY
Pathology; 2024 Feb; 56(1):122-124. PubMed ID: 37657990
[No Abstract] [Full Text] [Related]
2. Image Analysis of HER2 Immunohistochemical Staining of Surgical Breast Cancer Specimens.
Yim K; Park HS; Kim DM; Lee YS; Lee A
Yonsei Med J; 2019 Feb; 60(2):158-162. PubMed ID: 30666837
[TBL] [Abstract][Full Text] [Related]
3. National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures.
Vani K; Sompuram SR; Fitzgibbons P; Bogen SA
Arch Pathol Lab Med; 2008 Feb; 132(2):211-6. PubMed ID: 18251579
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.
Reisenbichler ES; Horton D; Rasco M; Andea A; Hameed O
Am J Clin Pathol; 2012 Jan; 137(1):102-10. PubMed ID: 22180483
[TBL] [Abstract][Full Text] [Related]
5. Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
J Clin Pathol; 2011 Jun; 64(6):490-2. PubMed ID: 21415056
[TBL] [Abstract][Full Text] [Related]
6. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
[TBL] [Abstract][Full Text] [Related]
7. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests.
Bánkfalvi A; Boecker W; Reiner A
Int J Oncol; 2004 Oct; 25(4):929-35. PubMed ID: 15375542
[TBL] [Abstract][Full Text] [Related]
8. [Effect of staining condition on HER2 immunohisto chemistry of breast cancer tissues].
Luo XL; Xu FP; Luo DL; Lin XT; Zhu XL; Xu J; Chen J; Zhang W; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):760-3. PubMed ID: 24447555
[No Abstract] [Full Text] [Related]
9. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
Yildiz-Aktas IZ; Dabbs DJ; Bhargava R
Mod Pathol; 2012 Aug; 25(8):1098-105. PubMed ID: 22460807
[TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
11. HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.
Nishimura R; Okamoto N; Satou M; Kojima K; Tanaka S
Diagn Cytopathol; 2016 Apr; 44(4):274-9. PubMed ID: 26800514
[TBL] [Abstract][Full Text] [Related]
12. HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5).
Horimoto Y; Onagi H; Watanabe J; Hayashi T
Pathol Int; 2024 Feb; 74(2):99-101. PubMed ID: 38197542
[No Abstract] [Full Text] [Related]
13. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.
Fitzgibbons PL; Murphy DA; Dorfman DM; Roche PC; Tubbs RR;
Arch Pathol Lab Med; 2006 Oct; 130(10):1440-5. PubMed ID: 17090184
[TBL] [Abstract][Full Text] [Related]
14. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH.
Yoon N; Do IG; Cho EY
APMIS; 2014 Sep; 122(9):755-60. PubMed ID: 24372629
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.
Luhtala S; Staff S; Barok M; Tanner M; Isola J
Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):212-219. PubMed ID: 27389555
[TBL] [Abstract][Full Text] [Related]
16. Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Scheel AH; Penault-Llorca F; Hanna W; Baretton G; Middel P; Burchhardt J; Hofmann M; Jasani B; Rüschoff J
Diagn Pathol; 2018 Mar; 13(1):19. PubMed ID: 29530054
[TBL] [Abstract][Full Text] [Related]
17. Fixation time does not affect expression of HER2/neu: a pilot study.
Ibarra JA; Rogers LW
Am J Clin Pathol; 2010 Oct; 134(4):594-6. PubMed ID: 20855640
[TBL] [Abstract][Full Text] [Related]
18. A two-phase study model for the standardization of HER2 immunohistochemical assay on invasive ductal carcinoma of the breast.
Sampatanukul P; Chaiwun B; Wongwaisayawan S; Suwanagool P; Vinyuvat S; Karalak A; Praditphol N; Paueksakon P; Ruangvejvorachai P; Field AS; Wannakrairot P
J Med Assoc Thai; 2005 Nov; 88(11):1680-8. PubMed ID: 16471119
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer.
Horiguchi J; Koibuchi Y; Iijima K; Yoshida T; Yoshida M; Takata D; Oyama T; Iino Y; Morishita Y
Int J Mol Med; 2003 Dec; 12(6):855-9. PubMed ID: 14612957
[TBL] [Abstract][Full Text] [Related]
20. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
